Download now: The Downfall of Cable, and the Rise of 5G!

The Secret to Quick and Easy Biotech Stock Returns

Written by Jason Stutman
Posted November 9, 2019

Do yourself a favor and take a moment to access your personal calendar to mark this date down: November 21, 2019.

Right now, I’m sure that might seem like an arbitrary day, but it’s a day that could change your financial well-being forever, and in ways that are difficult to even imagine.

You see, in less than a month, when November 21 rolls around, I’m going to let you in on a stock trader’s secret: Every day, a select group of investors has been hitting double- and triple-digit returns that are right under your nose, and with virtually zero effort.

These investors are armed with little more than a list of ticker symbols and a schedule. They’ve been compounding their wealth using this method for years, and they don’t plan on stopping anytime soon.

More importantly, you’ll soon have the opportunity to join them.

It Happens Like Clockwork

If you find I’m being too vague, let me give you some specifics:

In a single month, these investors banked close to double their money on Ascendis Pharma (NASDAQ: ASND), as the stock climbed from $69.17 to $125.53 in a single day of trading.

They were absolutely ecstatic, as Bio-Path Holdings (NASDAQ: BPTH) exploded in value to $38.86 from just $2.00.

And this group of investors also took 65% on Axovant Gene Therapies (NASDAQ: AXGT) in a single day.

Add in Daré Bioscience (NASDAQ: DARE), Dermira, Inc. (NASDAQ: DERM), and PhaseBio (NASDAQ: PHAS), which returned gains of 103.9%, 97.4%, and 88.8%, respectively...

Again, all in the span of one month.

I understand returns like these will seem like a pipe dream to most investors, but if you happen to be feeling skeptical, feel free to look all those tickers up. I assure you, those gains are real.

These kinds of trading events, mind you, aren’t exclusive to any particular time frame. They happen year-round and in bountiful frequency. All you need to do as a trader is know how to find them.

A Stock Picker’s Paradise

If you haven’t done so already, take a moment to look back at the aforementioned stocks and ask yourself what they all have in common. Aside from each one trading on the Nasdaq stock exchange, you’ll find that these are all small biotechnology firms.

More specifically, these are small biotechnology firms in the development stage. Most of them don’t have a single commercial product on the market yet, but the promise of the therapeutics they’re developing will cause the market to go into a sudden frenzy given certain developments.

Regulatory decisions, clinical data releases, and FDA approvals regularly send share prices of these stocks flying. Better yet, these events happen on a fairly tight schedule, so trading in this market is a stock picker’s paradise. You just have to know the dates and how likely a drug is to be approved.

Of course, most people don’t have the medical know-how to accomplish this with any real level of precision, but given the right resources, locating biotech stocks like these, right before they explode, is surprisingly easy.

You see, over the last few years I’ve been securing a network of doctors, analysts, and former bench scientists who have worked in the very same kinds of labs that innovative drugs are being developed in today. Jointly, I’ve put together a private calendar, marking down critical catalyst dates of small biotech stocks that most people will never even know the names of.

Put the two together, and you get what is easily the single most compelling trading strategy I’ve come across in my entire career, a strategy I’ll be sharing with readers less than a month from today.

If you want in on this opportunity, all I can tell you right now is to keep an eye out in the coming weeks. We’re going to run a brief informational webinar on November 21 with all the details, and registration will be opening shortly.

Keep an eye out for more details on that next week.

Until next time,

  JS Sig

Jason Stutman

follow basic @JasonStutman on Twitter

Jason Stutman is Wealth Daily's senior technology analyst and editor of investment advisory newsletters Technology and Opportunity and Topline Trader. His strategy for building winning portfolios is simple: Buy the disruptor, sell the disrupted.

Covering the broad sector of technology and occasionally dabbling in the political sphere, Jason has written hundreds of articles spanning topics from consumer electronics and development stage biotechnology to political forecasting and social commentary.

Outside the office Jason is a lover of science fiction and the outdoors. He writes through the lens of a futurist, free market advocate, and fiscal conservative. Jason currently hails from Baltimore, Maryland, with roots in the great state of New York.

Buffett's Envy: 50% Annual Returns, Guaranteed